HIPEC improves overall survival in recurrent epithelial ovarian cancer
Pramesh CS, Director at Tata Memorial Hospital, shared a recent article by Jean-Marc Classe on X:
“HIPEC improves overall survival in recurrent epithelial ovarian cancer. Level 1 evidence now. Took 10 years to do the trial, but these are the kinds of trials we need. Surgical trials, with overall survival (not DFS) as endpoint.”
Authors: Jean-Marc Classe, Pierre Meeus, Delphine Hudry, Romuald Wernert, François Quenet, Frédéric Marchal, Gilles Houvenaeghel, Anne-Sophie Bats, Fabrice Lecuru, Gwenaël Ferron, Cécile Brigand, Dominique Berton, Laurence Gladieff, Florence Joly, Isabelle Ray-Coquard, Sylvaine Durand-Fontanier, Gabriel Liberale, Marc Pocard, Constantin Georgeac, Sébastien Gouy, Jean-Marc Guilloit, Frédéric Guyon, Cristina Costan, Jean-Marc Rousselet, Lara de Guerké, Naoual Bakrin, Emilie Brument, Elodie Martin, Bernard Asselain, Loïc Campion and Olivier Glehen
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023